Author

W. Versees

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 4 Bioengineering· 2 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 7 Research Focus:drug response / drug discovery· 5 Organism:human· 3 Assay:protein structure· 3 Research Focus:protein folding & dynamics· 2 Organism:bacteria (other)· 1 Research Focus:cell signaling & trafficking· 1 Assay:CRISPR screen· 1

Frequent Co-Authors

J. Steyaert· 4 shared E. Pardon· 3 shared S. Ballet· 3 shared A. Wohlkonig· 2 shared B. Fischer· 2 shared C. Galicia· 2 shared C. J. Gloeckner· 2 shared D. Chatterjee· 2 shared

Activity by Year

2021-2024 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersBiochemistry

J. Steyaert

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

Identification and characterization of nanobodies acting as molecular chaperones for glucocerebrosidase through a novel allosteric mechanism

T. Dal Maso, C. Sinisgalli, G. Zilio, I. Tessari, E. Pardon, J. Steyaert, S. Ballet, E. Greggio, W. Versees, N. Plotegher

This study identifies nanobodies that act as molecular chaperones for glucocerebrosidase, improving its activity and stability, with potential therapeutic applications for Gaucher and Parkinson's diseases.

bioRxiv · Mar 25, 2024 · PreprintBiochemistry

Development of LRRK2 designed ankyrin-repeat proteins

V. Dederer, M. Sanz Murillo, E. P. Karasmanis, K. S. Hatch, D. Chatterjee, F. Preuss, K. R. Abdul Azeez, L. V. Nguyen, C. Galicia, B. Dreier, A. Pluckthun, W. Versees, S. Mathea, A. E. Leschziner, S. L. Reck-Peterson, S. Knapp

This study develops a high-affinity DARPin that binds to LRRK2's WD40 domain, improving structural analysis and revealing its role in disrupting LRRK2 filaments and Rab8A phosphorylation.

bioRxiv · Nov 14, 2023Biochemistry

Structural insights in the GTP-driven monomerization and activation of a bacterial LRRK2 homologue using allosteric nanobodies

C. Galicia, G. Guaitoli, M. Fislage, C. J. Gloeckner, W. Versees

This paper solves the structure of a bacterial Roco protein in its GTP-bound state using cryo-EM and nanobodies, revealing conformational changes and allosteric activation mechanisms.

bioRxiv · Nov 13, 2023 · PreprintBiochemistry

Nanobody CDR3 mimetics enhance SOS1-catalyzed nucleotide exchange on RAS

K. Van holsbeeck, B. Fischer, S. Gonzalez, C. Gadais, W. Versees, J. C. Martins, C. Martin, A. Wohlkonig, J. Steyaert, S. Ballet

This study shows that CDR3 mimetics can enhance SOS1-catalyzed nucleotide exchange on RAS, demonstrating functional modulation of protein-protein interactions through structural mimicry of a nanobody.

bioRxiv · Dec 9, 2022 · PreprintBioengineering

Competitive, connective and allosteric Nanobodies that modulate the SOS1-RAS protein-protein interactions and tune the nucleotide exchange rate as a starting point for drug design

B. Fischer, T. Uchanski, A. Sheryazdanova, S. Gonzalez, A. N. Volkov, E. Brosens, T. Zogg, V. V. Kalichuk, S. Ballet, W. Versees, A. A. Sablina, E. Pardon, A. Wohlkonig, J. Steyaert

The paper introduces methods to discover Nanobodies that modulate SOS1-RAS interactions and nucleotide exchange rates, with potential applications in drug design.

bioRxiv · Dec 6, 2022 · PreprintBioengineering

Deep mutational scanning of essential bacterial proteins can guide antibiotic development

L. Dewachter, A. N. Brooks, K. Noon, C. Cialek, A. Clark-ElSayed, T. Schalck, N. Krishnamurthy, W. Versees, W. Vranken, J. Michiels

This study uses deep mutational scanning on E. coli proteins to identify antimicrobial targets and guide drug development by analyzing mutation effects and resistance potential.

bioRxiv · May 23, 2022Microbiology

Nanobodies as allosteric modulators of Parkinson's disease-associated LRRK2

R. K. Singh, A. Soliman, G. Guaitoli, E. Störmer, F. von Zweydorf, T. Dal Maso, L. Van Rillaer, S. H. Schmidt, D. Chatterjee, E. Pardon, S. Knapp, E. J. Kennedy, J. Steyaert, F. W. Herberg, A. Kortholt, , W. Versees

This study identifies and characterizes Nanobodies that modulate LRRK2 activity through non-ATP-competitive mechanisms, offering new tools for Parkinson's disease research and therapy.

bioRxiv · Aug 30, 2021Biochemistry